GAITHERSBURG, Md., March 15 /PRNewswire-FirstCall/ -- MedImmune, Inc. announced today that it has added five new vice presidents to its management team. The newly hired team members include Allan Darling, Ph.D., vice president, corporate quality control; Gary B. Ebbert, Ph.D., vice president, antibody and small molecule manufacturing; Bahija Jallal, Ph.D., vice president, translational sciences; and Douglas B. Willner, vice president, sales training. MedImmune also promoted Frank D. Czworka, Jr., formerly regional business director, to vice president, sales, infectious disease.
“MedImmune continues to vest our successful leaders with increasing levels of responsibility. Frank Czworka has made substantial contributions to our sales organization over the past six years and will have an increased opportunity to contribute to our future through his new role leading our infectious disease sales force,” said David M. Mott, chief executive officer and president. “We also continue to attract world-class talent to MedImmune as evidenced by the additions of Drs. Darling, Ebbert and Jallal and Mr. Willner to our organization. We are excited to have these dynamic and talented individuals join our team and look forward to their contributions to our future success.”
New Executives at MedImmune
Allan Darling, Ph.D., joins MedImmune as vice president, corporate quality control, with primary responsibility for overseeing quality control at the company’s commercial production facilities in support of antibody, vaccine and small molecule manufacturing activities. Prior to joining MedImmune, Dr. Darling was employed by BioReliance Invitrogen Bioservices where he held several positions of increasing responsibility, leading to his most recent role as vice president, global operations. Previously, Dr. Darling held positions at United Kingdom-based companies and institutions such as Q-One Biotech, the Beatson Institute for Cancer Research and the Medical Research Council in Glasgow. Dr. Darling holds a bachelor’s degree in biological sciences from the University of Edinburgh and a doctorate from the University of Dundee.
Gary B. Ebbert, Ph.D., has been appointed vice president, antibody and small molecule manufacturing for MedImmune where he is responsible for all antibody and small molecule commercial manufacturing activities at the company’s production facilities. He will also ensure regulatory compliance for the company’s manufacturing operations and will lead infrastructure enhancements in support of future growth in this area. Dr. Ebbert joins MedImmune from King Pharmaceuticals, Inc. where he served as executive vice president, worldwide manufacturing. Previously, Dr. Ebbert was president and chief executive officer of Ebquest Healthcare, Inc. Dr. Ebbert also served as the corporate vice president, technology at Sanofi-Pasteur (formerly Aventis Pasteur) where he was responsible for identifying, evaluating and incorporating new technology into the company’s global industrial operations. Prior to his position as corporate vice president, Dr. Ebbert served as vice president, operations at Aventis Pasteur. Dr. Ebbert earned his doctorate from Temple University in pharmaceutics and his master’s degree in biological science with a concentration in molecular/cell biology from East Stroudsburg University in Pennsylvania.
Bahija Jallal, Ph.D., will join MedImmune as vice president, translational sciences. In her new role, Dr. Jallal will develop the translational sciences group to assess biomarkers and establish a preclinical knowledge base for MedImmune’s therapeutic agents that will guide clinical studies. She will also direct the toxicology/pathology, clinical assays and in vivo/ex vivo biology efforts for MedImmune. Dr. Jallal joins MedImmune from Chiron Corporation where she served as vice president, drug assessment and development. She also successfully established the translational medicine group at Chiron. Previously, Dr. Jallal worked at Sugen, Inc. where she held positions of increasing responsibility until her departure. Dr. Jallal received a master’s degree in biology from the Universite de Paris VII in France, and her doctorate in physiology from the University of Pierre & Marie Curie in Paris. She conducted her postdoctoral research at the Max Planck Institute of Biochemistry in Martinsried, Germany.
Douglas B. Willner has joined MedImmune as vice president, sales training where he is responsible for building and managing the various sales training programs. Mr. Willner joins MedImmune from Serono, Inc. where he served as executive director, learning and organizational excellence. Previously, Mr. Willner was director, leadership and development, for GlaxoSmithKline Consumer Healthcare. He also has extensive experience in sales, sales management, human resources and operations. Mr. Willner holds a bachelor of science in business and economics from the University of Connecticut.
Executive Promotion
In his new position as vice president, sales, infectious disease, Frank D. Czworka, Jr. will lead sales force activities for MedImmune’s infectious disease medicines. Mr. Czworka joined MedImmune in May 2000 as an area business manager leading the biotechnology sales specialist launch operations in Georgia, Alabama and Florida. In July 2001, he was promoted to regional business director for the Northeast region where he managed personnel expansion from 39 representatives to its current size of nearly 100 representatives. Prior to joining MedImmune, Mr. Czworka held a number of positions at TAP Pharmaceuticals, including professional sales representative, government account manager, regional and home office program training manager and district sales manager. Mr. Czworka holds a bachelor of science and arts degree in marketing from the University of Central Florida.
About MedImmune
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,200 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company’s website at http://www.medimmune.com.
MedImmune, Inc.
CONTACT: Media: Kathryn Barrett, +1-301-398-4320 or Clarencia Stephen,+1-301-398-4073, Investors: Peter Vozzo, +1-301-398-4358, all of MedImmune,Inc.
Web site: http://www.medimmune.com//
